With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
SYNTAX and MAIN-COMPARE suggest a role for PCI in subsets of patients with left main disease; however, in current ACC/AHA guidelines this remains a class III indication. Dr. Turco chairs a roundtable with interventionalists Drs Kandzari and Park and surgeon Dr Sabik.
Since BARI, CABG has been the gold standard for patients with diabetes and multivessel disease. However, SYNTAX suggests an increasing role for PCI and BARI 2D highlights the importance of optimal medical therapy. Dr. Boden leads a multidisciplinary discussion with Drs. Holmes and Taggart.
With the recent approval of a third-generation thienopyridine, choice of agent can be added to the list of considerations in the management of ACS patients, as well as the appropriate timing and dosing of thienopyridine. Using some case vignettes, Dr. King leads a discussion with Drs. Bhatt and Steg on their clinical decision-making.
From SOLACI 2009 in Rio de Janeiro. Dr. Mahmud hears how Dr. Feres interprets the data on antiplatelet/antithrombin strategies for his practice in Brazil.
Transcatheter aortic valve implantation (TAVI) has been approved in Europe since 2007, whereas these devices are just entering large-scale research trials in the United States. Dr. Popma leads a panel discussion with European interventionalist Dr. Eberhard Grube and surgeon Dr. Neil Moat on their experiences with TAVI.
Given SYNTAX, is left main stenting ready for primetime? Do the NCDR data lay to rest DES safety concerns? Recorded at EuroPCR 2009, Dr. Popma discusses the current status and future roles of PCI and DES with Drs.Gershlick and Tamburino.
When choosing between DES and BMS or among the various DES, how much weight should be given to 1-year data vs the totality of evidence? What is the duration of stent thrombosis risk? Dr. Leon leads a panel discussion to address these issues with Drs. Kandzari and Yeung.
Learn about the current status of less-invasive strategies to repair thoracic aneurysms as Dr. Mack leads a discussion with vascular surgeons, Drs. Kasirajan and Woo. Which cases are amenable to endovascular repair and which require open surgery?
On February 3, 2009, the FDA's Cardiovascular and Renal Drugs Advisory Committee unanimously voted to recommend approval of the novel thienopyridine prasugrel for use in ACS patients undergoing PCI. Drs. Nissen, Ohman, Kandzari, Topol, and Steg each give their take on the likely implications for clinical practice and remaining issues of concern in the optimal management of patients with ACS.
Acknowledgements
CME provider: Medscape.
The drug-eluting stents theme is supported by an independent educational grant from Medtronic, Inc., Daiichi Sankyo, Inc., and Eli Lilly & Co.
Steering committee
The steering committee members are active in overseeing the development and direction of this educational series.